NIH Hands Eye-Saving Peptides to Biotech Firm Exclusive Rights
Published Date: 4/1/2026
Notice
Summary
The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Exclusive License for PEDF Eye Treatment
The National Eye Institute is considering granting Perpetual Biosciences, Inc. an exclusive, royalty-bearing license (possibly worldwide) to develop and sell chemically synthesized PEDF peptide therapeutics for human eye diseases, including retinitis pigmentosa, glaucoma, and age-related macular degeneration. The notice says this could potentially help millions with retinal degeneration and that written comments or license applications must be received by April 16, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in